Tonix Pharma (TNXP) Says TNX-102 SL Phase 3 Did Not Meet Primary Endpoint in Fibromyalgia

Go back to Tonix Pharma (TNXP) Says TNX-102 SL Phase 3 Did Not Meet Primary Endpoint in Fibromyalgia

Cantor Fitzgerald Downgrades Tonix Pharma (TNXP) to Hold

September 7, 2016 7:27 AM EDT

Cantor Fitzgerald downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Hold with a price target of $1.00 (from $5.00).

For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.

Shares of Tonix Pharma closed at $0.92 yesterday.

... More